Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1
Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2
Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year
Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients
Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3.
Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile.
'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients,' said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. 'These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients.'
This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer.
Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year.
About PSMAddition study
PSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3.
About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan)
Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414).
Novartis and radioligand therapy (RLT)
Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast.
Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.
Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.
References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). ClinicalTrials.gov identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. https://clinicaltrials.gov/study/NCT04720157. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/j.esmoop.2023.101194 Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. https://www.uchicagomedicine.org/cancer/types-treatments/prostate-cancer/treatment/lutetium-177-psma-therapy-for-prostate-cancer. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249
# # #
Novartis Media Relations
E-mail: [email protected]
Novartis Investor RelationsCentral investor relations line: +41 61 324 7944
E-mail: [email protected]
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
22 minutes ago
- Boston Globe
The FDA is targeting orange juice. Here's why, and what the science says.
Orange juice contains nutrients including calcium and Vitamin C. But some nutritionists argue that's not enough to make up for the unnecessary calories and natural sugars. 'Juices are a dilemma,' said Peter Lurie, the executive director of the nonprofit Center for Science in the Public Interest, which advocates for a healthy and safe food supply. Get Winter Soup Club A six-week series featuring soup recipes and cozy vibes, plus side dishes and toppings, to get us all through the winter. Enter Email Sign Up The American Academy of Pediatrics recommends instead eating real fruit, which contains more fiber than juice. The association advises against giving fruit juice to infants except to manage constipation. It also advises limiting how much juice parents should give older children, such as no more than 4 ounces per day for kids 1 to 3 years old. Advertisement 'If you're going to have a small amount of juice, it's not going to be anything that anybody's going to worry about,' said Marion Nestle, a retired professor of nutrition, food studies and public health at New York University who called fruit juices 'delicious.' 'When you worry about juice is when it's in large amounts,' she added. Advertisement Even though leading orange juice brands do not contain added sugars, high levels of natural sugars can still be harmful, some experts said. 'Orange juice is sugar water,' said Barry Popkin, a professor of nutrition at the University of North Carolina. 'Every juice is essentially sugar water.' Once touted as part of a balanced breakfast, Americans are souring on orange juice. Consumers have gravitated toward other beverage options seen as healthier. Prices have risen. Production has stalled. And this has become a problem for Florida's orange producers. The sugar content of the fruit grown in the state has been steadily dropping due to a bacterial disease afflicting the crop, exacerbated after Hurricane Irma struck in 2017. In 2022, Florida trade groups representing the state's citrus growers and citrus juice industry petitioned the FDA to lower the minimum fruit sugar levels for pasteurized orange juice. The FDA sets a minimum standard for the sugar content in order to call a drink 'pasteurized orange juice,' the kind commonly sold at grocery stores without added sugars. If manufacturers fall below that threshold, they are essentially no longer allowed to call their products 'pasteurized orange juice." Florida orange industry groups said lowering that threshold would protect their business and reduce orange imports from other countries while going unnoticed by consumers. Sugar per serving would lower from 18 grams to 17 grams, according to nutritional label samples provided to the FDA by the industry. Other nutrients would be largely unaffected to the change. Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary both pledged to examine this proposal during congressional hearings when pressed by Sen. Ashley Moody (R-Florida). Advertisement Some nutrition experts said if Kennedy wanted to advance his 'Make America Healthy Again' agenda, which included pledges to improve the diets of children, he should champion more sweeping regulations broadly targeting sugars and sodium. 'If one is serious about sugar in the American diet, we need an across the board approach,' Lurie said.
Business Wire
22 minutes ago
- Business Wire
Bone Solutions Announces Five New Patents Awarded in FY25, Further Enhancing Its Core Mg OSTEOCRETE Technology
COLLEYVILLE, Texas--(BUSINESS WIRE)-- Bone Solutions Inc., an orthobiologics technology company located in Colleyville, Texas, announced today its fifth patent awarded this year from the U.S. Patent and Trademark Office (USPTO) related to Mg OSTEOCRETE, a portfolio of patents that includes current and future configurations, as well as novel delivery systems. "Bone Solutions is furthering its mission to improve patient outcomes." These five patents further expand Bone Solutions' industry footprint and allow surgeons and patients to further benefit from the advantages of the Bone Solutions proprietary magnesium-based technology. Mg OSTEOCRETE and Mg OSTEOINJECT (an injectable version of the product) are fast-setting bone substitutes that remodel into bone over time through creeping substitution, meaning they provide needed support to the defect or void during the healing process while transforming into bone at an optimal rate. 'We are pleased to announce the addition of five new patents supplementing our various technologies, ensuring our continued growth and profitability for the company's future,' said Drew Diaz, CEO of Bone Solutions. 'By leveraging our existing technology, Bone Solutions is furthering its mission to improve patient outcomes through our superior magnesium-based orthopedic solutions." The magnesium component of Mg OSTEOCRETE is the significant differentiator from other bone substitutes on the market. The crystallization reaction from magnesium oxide and the blend of phosphate-based materials allows for ideal osteoconductivity of the product. As a result, Mg OSTEOCRETE and Mg OSTEOINJECT set and cure in situ without migration. The material stimulates cell adhesion, proliferation, and formation of the bone extracellular matrix by osteoblast cells, thus promoting bone growth. In addition to the superior biological performance of the material, the handling characteristics and formulation are ideal for clinical use. Ready for use after only 30 seconds of mixing, the material is moldable or injectable and is cohesive and adhesive to the area it fills. Once implanted, the material sets quickly, is drillable after only two minutes, and is also radiopaque. Mg OSTEOCRETE and Mg OSTEOINJECT are currently being distributed to facilities and surgical centers nationwide for immediate clinical use. About Bone Solutions Inc. Bone Solutions Inc. is a specialized medical device company dedicated to improving clinical outcomes through biologically safe, fully resorbable magnesium-based orthopedic implant solutions, with a focus on addressing complex procedures and cost reduction. The company is developing various new orthopedic technologies within its FDA-cleared magnesium-based platform.
Newsweek
23 minutes ago
- Newsweek
Costco Recall Update Nationwide as Fatal Warning Issued
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Costco, one of America's largest warehouse retailers, recently alerted consumers to several nationwide product recalls—including warnings classified as potentially fatal. The recalls include pools and food sold by the retail giant, affecting customers across the United States. Why It Matters According to the U.S. Food and Drug Administration (FDA), foodborne illness outbreaks and unsafe consumer goods remain leading causes of preventable hospitalizations and injuries in the U.S. A Costco store is seen on September 23, 2022 in Monterey Park, California. A Costco store is seen on September 23, 2022 in Monterey Park, California.) What To Know The following products sold at Costco were recalled in July: Pura announced a voluntary corrective action for certain Pura 4™ diffusers after discovering that magnets inside the front cover may detach over time. While no injuries have been reported, detached magnets can pose serious health risks if swallowed, particularly for children or pets. In response, Pura is offering free replacement covers to consumers with affected units. Users can continue using the diffuser by removing and safely discarding the current cover while waiting for the replacement. Pura advises keeping the diffuser out of reach of children and animals during this interim period. Customers can confirm if their diffuser is impacted and request a free replacement cover by visiting Support is also available at 855-394-5292 or via email at replacement@ The company emphasized its ongoing commitment to customer safety. Bestway, in cooperation with the U.S. Consumer Product Safety Commission, has issued a safety recall for select Power Steel, Steel Pro, and Coleman Power Steel aboveground pools sold between 2008 and 2024. The recall targets 48-inch or taller models with external compression straps, which children may use as footholds to access the pool unsupervised—posing a significant drowning risk. Affected products include item numbers sold through Costco between 2017 and 2024, such as 1099149, 1179351, 1274360, and others listed in the recall notice. Pools with internal straps or heights under 48 inches are not impacted. Customers are urged to verify if their pool is affected by checking strap placement and visiting to request a free, easy-to-install repair kit. In the meantime, pool access should be strictly controlled. For assistance, call 844-593-4003 or email BWrecallsupport5516@ Intex Recreation issued a voluntary recall of select aboveground pools 48 inches and taller, sold between 2002 and 2012, due to a potential drowning hazard. The affected models feature exterior compression straps that can serve as a foothold for children, enabling unsupervised pool access. The recall includes 48" and 52" Metal Frame and Ultra Frame pools, as well as certain Costco-sold models. Pools manufactured from 2013 onward are not impacted, as they use an internal strap system to eliminate the hazard. Customers are urged to visit or call 1-800-549-8829 to determine if their pool is affected and request a free repair kit. Until repaired, pool access should be strictly restricted or the pool drained. Intex also advises following the U.S. Consumer Product Safety Commission's Pool Safely guidelines to prevent accidents. Mondelēz Global issued a voluntary recall of a limited number of 40-count cartons of RITZ Peanut Butter Cracker Sandwiches, sold at select Costco Warehouses and Business Centers between June 2 and July 9, 2025. The recall affects cartons that may contain peanut butter cracker sandwiches but are incorrectly labeled as the cheese variety on the individual packs. While the outer cartons are correctly labeled and carry an allergen warning for peanuts, the mislabeling on individual wraps poses a serious risk for those with peanut allergies. The recalled items can be identified by Best When Used By dates ranging from November 1, 2025, to January 22, 2026, printed on the top of the package. Consumers with peanut allergies are urged not to consume the product and should return it to Costco for a full refund. Questions can be directed to Mondelēz at 1-844-366-1171, available 24/7. Members and the general public can reference Costco's official recall webpage for updates and expanded details.
